Thymalfasin is under clinical development by SciClone Pharmaceuticals Holdings and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Thymalfasin’s likelihood of approval (LoA) and phase transition for Thymic Carcinoma took place on 28 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 28 May 2021 increased Thymalfasin’s Phase Transition Success Rate (PTSR) for Thymoma (Thymic Epithelial Tumor).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Thymalfasin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Thymalfasin overview

Thymalfasin (Zadaxin) is a synthetic polypeptide consisting of 28 amino acids, a synthetic version of thymosin alpha 1, a substance found naturally in the circulation and produced in the body's thymus gland. It is formulated as an injection for the sub-cutaneous route of administration. It is used different indications such as chronic Hepatitis B, cancer adjuvant, vaccine enhancer and immunostimulant. It is used as an adjuvant for influenza vaccination in immunocompromised individuals.

Thymalfasin is under development for the treatment of acute pneumonia, thymoma, thymic carcinoma and sepsis. It was also under development for the treatment of advanced stage metastatic malignant melanoma (US) and non-small cell lung cancer.

SciClone Pharmaceuticals Holdings overview

SciClone Pharmaceuticals Holdings (SciClone) develops and commercializes products for the treatment of cancer and immunology. The company’s pipe line products include daya sin, zotye, nomic, angel, ando student, he lesheng, mesna, methotrexate injection, algos and faroda among others. Its under-development products comprise Naxitamab, Circumcising, Vibativ, Vaborem, RRx-001, PEN-866, PT-112, ABTL-0812 and HSP90-PI3K. It also markets Zadaxin (Thymalfasin), an immunostimulatory agent indicated for the treatment of hepatitis as an immune system enhancer. SciClone is headquartered in Hongkong.

Quick View Thymalfasin LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Thymalfasin
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Infectious Disease
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.